Decellularization of Extracellular Matrix from Equine Skeletal Muscle.

The research article presents a study focused on creating a cell-free biomaterial from horse muscle tissues, providing a promising path for regenerative medical treatments for musculoskeletal diseases. The study also tested whether this cell-free material could support the growth and survival of induced pluripotent stem cells (iPSCs) in an in vitro environment.

Procedure and Methodology

• The research team set out to produce an acellular biomaterial from horse skeletal muscle and test if it could support the in vitro culture of horse iPSCs.
• They undertook this by using samples from the Biceps femoris, which were frozen at -20°C for 4 days, before incubating them in 1% sodium dodecyl sulfate (SDS), 5 mM EDTA + 50 mM Tris and 1% Triton X-100.
• The decellularization process, or the removal of cells from the tissue, was assessed by the absence of residual nuclei—visualized using histological and 4’,6-diamidino-2-phenylindole (DAPI) analysis.
• The team also examined how well the decellularization preserved the extracellular matrix (ECM) proteins and architecture with techniques such as immunofluorescence, immunohistochemistry, and scanning electron microscopy.

Result and Observation

• Findings showed that the decellularized biomaterial exhibited no remaining nuclei and muscle fibers, indicating a successful decellularization process.
• In addition to this, the structure of the ECM, the vascular network, and proteins such as laminin, fibronectin, elastin, collagen III and IV were preserved.
• After decellularization, the scientists introduced iPSCs, which were present after 9 days of incubation. This result suggested that the cell-free material provided a conducive environment for iPSC survival.

Conclusion

• From the results, the authors conclude that the ECM biomaterial derived from decellularized horse skeletal muscle demonstrates clear potential for iPSC adhesion. As such, it represents a promising biomaterial for therapeutic use in regenerative medicine, specifically for treating musculoskeletal diseases.